Sunshine Biopharma Inc (SBFM) Stock Analysis
Verdict: AVOID
Relentless dilution and negative earnings surprises override generic drug revenue growth, leaving SBFM highly vulnerable to recapitalization risk.
Investment score: 23/100
Analysis as of
Is Sunshine Biopharma Inc stock worth reviewing? AI model thesis
The model views SBFM as an uninvestable micro-cap for core equity investors due to severe share dilution, recurring negative earnings surprises, and listing compliance stress.
7-factor investment score
- Valuation: 25/100 (weight 20%)
- Financial Health: 30/100 (weight 15%)
- Technical Momentum: 10/100 (weight 15%)
- Earnings Quality: 15/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 40/100 (weight 10%)
- Risk-Adjusted Return: 15/100 (weight 15%)
Sunshine Biopharma Inc opportunities and risks
What speaks for SBFM
- Canadian generic drug portfolio expansion
What speaks against SBFM
- Chronic per-share value dilution
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| SBFM | n/a | 0.0x | 2.3x | 29.8% | -16.5% | -449.6% |
| ISCO | n/a | 0.2x | n/a | 54.8% | -6.1% | 15.4% |
| OGEN | n/a | 0.0x | 0.2x | 0.0% | 0.0% | -488.6% |
| ENZC | n/a | 0.0x | n/a | 0.0% | 0.0% | -29.1% |
| LABT | n/a | 0.0x | 0.2x | 0.0% | 0.0% | -251.4% |
| CRIS | n/a | 0.3x | 0.1x | 99.3% | -490.3% | -2212.3% |
| Peer median | n/a | 0.0x | 0.1x | 0.0% | 0.0% | -251.4% |
Frequently asked questions about Sunshine Biopharma Inc (SBFM)
Is SBFM stock a good investment?
The cached TradeMates AI model rates Sunshine Biopharma Inc as AVOID with an investment score of 23/100. The model views SBFM as an uninvestable micro-cap for core equity investors due to severe share dilution, recurring negative earnings surprises, and listing compliance stress. This is algorithmic model output, not personal investment advice.
Is SBFM stock a buy?
The TradeMates model verdict for SBFM is AVOID with an investment score of 23/100. Treat this as a model signal to review, not a personal buy recommendation.